Latest News on HROW

Financial News Based On Company


Advertisement
Advertisement

HROW: Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6794357
Harrow Inc. (HROW) filed an 8-K form detailing a corporate presentation for the Jefferies Global Healthcare Conference, reporting record Q3 2026 revenue of $99.3 million, a 41% quarter-over-quarter increase. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, with an implied Q4 adjusted EBITDA of over $33 million. While strong revenue growth and flat SG&A are positive, concerns include $300 million in unsecured notes and reliance on a few core brands.

HROW: Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://quantisnow.com/insight/harrow-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6794357
Harrow Inc. (HROW) filed an SEC Form 8-K regarding Regulation FD Disclosure, Financial Statements, and Exhibits. The company posted record Q3 2026 revenue of $99.3M, a 41% increase quarter-over-quarter, and reaffirmed its FY2026 guidance of $350M-$365M, with Q4 adjusted EBITDA projected to be over $33M. Historically, HROW's stock has shown mixed reactions to previous headlines, with a median move of 2.2% in either direction after such announcements.

Harrow Inc. nears $350M 2026 revenue goal after strong Q3 growth and expanded sales efforts.

https://pluang.com/en/news-feed/harrow-pertumbuhan-pendapatan-kuat-leverage-operasi-ke-depan
Harrow Inc., an ophthalmology company, reported strong Q3 growth in its products VEVYE (35%) and IHEEZO (62%), driven by expanded sales efforts. The company is on track to achieve its ambitious $350 million revenue target by 2026, supported by a licensing and sales strategy that keeps R&D costs low. Continued momentum and potential approval for its G-MELT drug could significantly boost its stock value by 2027.

Harrow (HROW) Shares Moved, What Is Drawing Attention Today?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-shares-moved-what-is-drawing-attention-today
Harrow (HROW) has seen its shares move after reporting record third-quarter revenue of US$99.3 million, returning to profitability, and reaffirming its full-year revenue guidance. The company also launched its new HarrowRx pharmacy platform, leading to a 7-day share price return of 12.79%, although its year-to-date share price is down 41.15%. Analysts at Simply Wall St believe Harrow is 53% undervalued, with a fair value of $63 against a current price of $29.37, driven by its expansion into a broader branded ophthalmic portfolio and enhanced commercial infrastructure.

A London presentation will stream live Nov. 18; Harrow will also meet investors in New York.

https://www.stocktitan.net/news/HROW/harrow-to-participate-in-two-investor-conferences-in-87bmgv6cn7cl.html
Harrow (Nasdaq: HROW) announced its management will participate in two investor conferences in November 2026. These include the Craig-Hallum 17th Annual Alpha Select Conference in New York on November 17 for one-on-one investor meetings, and the Jefferies Global Healthcare Conference in London on November 18, featuring a presentation and investor meetings. The Jefferies presentation will be webcast live and a replay will be available for approximately 90 days.
Advertisement

Harrow to Participate in Two Investor Conferences in November

https://www.globenewswire.com/news-release/2026/11/12/3401420/0/en/harrow-to-participate-in-two-investor-conferences-in-november.html
Harrow (Nasdaq: HROW), a provider of ophthalmic disease management solutions, announced its participation in two investor conferences in November. Management will attend the Craig-Hallum 17th Annual Alpha Select Conference for 1x1 investor meetings and the 2026 Jefferies Global Healthcare Conference for a presentation and 1x1 meetings. The Jefferies presentation will be webcast live on the Company’s website.

HROW Reiterated by BTIG -- Price Target Maintained at $63

https://www.gurufocus.com/news/9192010/hrow-reiterated-by-btig-price-target-maintained-at-63
BTIG has reiterated a "Buy" rating for Harrow Inc (HROW), maintaining a price target of $63.00, reflecting confidence in the company's future performance in ophthalmic products. GuruFocus calculates HROW as undervalued by 33.6% with a GF Value™ of $45.69, despite concerns about its financial strength and loss-making status. Insider activity shows $450,000 in sales over the last three months, suggesting a cautious sentiment among some insiders.

Harrow Reports Record Third Quarter 2026 Revenue Driven by Branded Products

https://www.visionmonday.com/eyecare/article/harrow-reports-record-third-quarter-2026-revenue-driven-by-branded-products/
Harrow (Nasdaq: HROW) announced record third-quarter 2026 revenue of $99.3 million, a 41 percent sequential and 39 percent year-over-year increase, primarily driven by its branded products, which contributed $83.5 million. The company's CEO, Mark L. Baum, highlighted strong performance from Vevye, Triesence, and Iheezo, anticipating a strong fourth quarter with initial revenue from Tyrvaya and reaffirming full-year revenue guidance of $350 million to $365 million. Adjusted EBITDA is projected to exceed $40 million for the full year, with over $33 million expected in Q4, despite increased spending on NDA submissions and integration.

Harrow Inc (HROW) Q3 2026 Earnings Call Highlights: Record Revenue of $99. ...

https://uk.finance.yahoo.com/news/harrow-inc-hrow-q3-2026-070423572.html
Harrow Inc. (HROW) reported record Q3 2026 revenue of $99.3 million, a 41% sequential and 39% year-over-year increase, driven largely by a 62% rise in branded revenue. VEVYE and TRIESENCE showed strong growth, and the company reaffirmed its full-year revenue guidance. However, full-year Adjusted EBITDA guidance was significantly lowered due to first-half shortfalls and lower gross margins, and a key clinical study for IHEEZO did not meet its primary endpoint.

Harrow Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:08f889262094b:0-harrow-q3-earnings-call-highlights/
Harrow (HROW) reported record third-quarter revenue of $99.3 million but significantly reduced its full-year adjusted EBITDA outlook from $80-$100 million to over $40 million due to lower-than-expected margins and increased spending. The company maintained its full-year revenue guidance of $350-$365 million. Additionally, a clinical study for its IHEEZO anesthetic did not meet its primary endpoint, though management plans to leverage other study findings.
Advertisement

Harrow Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63090382/harrow-q3-2026-earnings-call-transcript
Harrow reported record third-quarter revenue of $99.3 million, a significant increase year-over-year, driven by strong performance from VEVYE, IHEEZO, and Triessence. The company reaffirmed its full-year revenue guidance of $350-$365 million, expecting a robust Q4 with contributions from newly acquired Tyrvaya. Harrow also updated its adjusted EBITDA outlook to over $40 million for the full year, reflecting strategic investments and accelerated R&D programs, and discussed the inconclusive primary endpoint of its Quell study but highlighted encouraging secondary and safety findings for IHEEZO.

Harrow Releases Q3 2026 Financial Results

https://news.alphastreet.com/harrow-releases-q3-2026-financial-results/amp/
Harrow, Inc. reported strong Q3 2026 financial results, with diluted earnings per share of $0.25, surpassing analyst estimates by 13.6%. The company's revenue reached $99.3M, a 39.0% increase year-over-year, driven significantly by VEVYE's performance. Full-year revenue guidance is set between $350.0M and $365.0M.

Harrow Affirms FY26 Sales Guidance of $350M-$365M

https://scanx.trade/stock-market-news/companies/harrow-affirms-fy26-sales-guidance-350m-365m/55806698
Harrow Inc. has reaffirmed its fiscal year 2026 sales guidance, maintaining a projected range of $350 million to $365 million. This guidance is consistent with prior expectations and slightly exceeds the consensus analyst estimate of $349.747 million, signaling the company's confidence in its revenue projections. The narrow gap between the lower bound of guidance and the analyst consensus suggests close alignment between market expectations and internal forecasts.

Harrow earnings on deck as investors eye profitability return By Investing.com

https://www.investing.com/news/earnings/harrow-earnings-on-deck-as-investors-eye-profitability-return-93CH-5012539
Harrow Inc. is set to report third-quarter earnings, with investors keenly watching for a return to profitability after a disappointing second quarter. Analysts anticipate earnings of 20 cents per share on revenue of $99.1 million, a significant improvement driven by the acquisition of TYRVAYA and expanded sales efforts. The company's stock is trading near its 52-week low despite strong analyst buy ratings, making the upcoming report a crucial catalyst.

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say

https://ca.finance.yahoo.com/news/harrow-hrow-reports-q3-earnings-230001670.html
Harrow (HROW) reported its Q3 2026 earnings, with revenue reaching $99.3 million, a 38.6% increase year-over-year, and EPS at $0.12. While revenue slightly surpassed the Zacks Consensus Estimate, EPS missed expectations. The article details key performance metrics, such as product sales and branded revenues, and notes that Harrow's shares have underperformed the S&P 500 composite in the past month, currently holding a Zacks Rank #5 (Strong Sell).
Advertisement

Harrow Announces Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/09/3398928/0/en/harrow-announces-third-quarter-2026-financial-results.html
Harrow (Nasdaq: HROW) announced strong financial results for the third quarter of 2026, reporting record revenue of $99.3 million, a 41% sequential and 39% year-over-year increase, largely driven by branded product sales. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and updated its Adjusted EBITDA guidance to over $40 million, anticipating a strong fourth quarter. Key product highlights include record revenues for VEVYE and TRIESENCE, and the recent acquisition of TYRVAYA, which is expected to contribute to fourth-quarter revenue.

Harrow stock hits 52-week low at 26.9 USD By Investing.com

https://uk.investing.com/news/stock-market-news/harrow-stock-hits-52week-low-at-269-usd-93CH-4962149
Harrow, Inc. (HROW) stock has fallen to a 52-week low of $26.90, representing a significant decline from its 52-week high of $54.85 and a year-to-date drop of 41.33%. Despite this downturn, InvestingPro analysis suggests the stock is undervalued, and analysts predict the company will be profitable this year with expected net income growth. Recent Q2 2026 financial results showed a wider-than-expected loss but an increase in revenue, with management reaffirming its full-year outlook.

Harrow stock hits 52-week low at 26.9 USD

https://www.investing.com/news/company-news/harrow-stock-hits-52week-low-at-269-usd-93CH-5005218
Harrow, Inc. stock recently hit a 52-week low of $26.90, significantly down from its high of $54.85, reflecting a 41.33% year-to-date drop. Despite this decline and a wider-than-expected loss in Q2 2026, analysts predict the company will be profitable this year, with InvestingPro suggesting the stock is undervalued. Investors can access further insights and 12 additional ProTips via an InvestingPro subscription.

How Investors May Respond To Harrow (HROW) EMR Prescribing Platform Launch

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-investors-may-respond-to-harrow-hrow-emr-prescribing-pla
Harrow (HROW) has launched HarrowRx, an EMR-integrated platform designed to streamline the prescribing and access of its ophthalmic products, including VEVYE. This initiative aims to improve patient access and reduce operational complexities by consolidating services into a single digital hub. The success of HarrowRx will be critical in converting prescriptions to paid usage and could reshape Harrow's investment narrative, although risks like pricing pressure and competition remain.

Harrow, Inc. (3IP.F) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/3IP.F/sec-filing/
This article provides an overview of Harrow, Inc. (3IP.F) stock, including its current delayed quote from Frankfurt and performance overview. As of November 3, 2026, the stock is trading at 24.60 EUR, showing no change. The performance data indicates that Harrow Inc.'s returns are not available for various periods, while the S&P 500 has seen positive returns.
Advertisement

Eye doctors can now prescribe Harrow medicines in software they already use

https://www.stocktitan.net/news/HROW/phil-partners-with-harrow-to-power-harrow-rx-one-prescribing-urzhvbg094eo.html
Harrow (Nasdaq: HROW) and PHIL Inc. have launched HarrowRx, a new prescribing and patient-access platform that allows eye care providers to e-prescribe Harrow’s branded ophthalmic portfolio directly within their existing electronic medical record (EMR) systems. This platform aims to simplify patient access to treatments like VEVYE® by integrating patient services, support, and affordability programs, thereby streamlining the process from prescription to fulfillment. The collaboration builds on an existing partnership that has already demonstrated positive impacts on patient access and affordability for eye care medications.

Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?

https://ca.finance.yahoo.com/news/harrow-hrow-expected-beat-earnings-140009935.html
Harrow (HROW) is expected to beat earnings estimates for the quarter ended September 2026, with a Zacks Earnings ESP of +44.00% and a Zacks Rank of #3. While the company anticipates a year-over-year decline in earnings per share, revenues are projected to increase by 39.4%. Investors should also consider other factors beyond earnings surprises when making investment decisions.

Harrow launches pharmacy platform for ophthalmic prescriptions

https://ca.investing.com/news/stock-market-news/harrow-launches-pharmacy-platform-for-ophthalmic-prescriptions-93CH-4921612
Harrow (NASDAQ:HROW) has launched HarrowRx, a new prescribing and pharmacy access platform for ophthalmic products. This platform integrates with existing electronic medical record systems used by eyecare professionals, streamlining prescription processes and connecting patients with support programs. Harrow believes it is the first platform of its kind developed by a U.S. ophthalmic pharmaceutical company.

Harrow Launches HarrowRx Platform

https://www.globenewswire.com/news-release/2026/11/02/3393010/0/en/harrow-launches-harrowrx-platform.html
Harrow, a leading provider of ophthalmic disease management solutions, has launched HarrowRx, a new prescribing and access pharmacy platform. This platform allows eyecare professionals to directly access Harrow's entire product portfolio within their existing electronic medical record (EMR) systems, simplifying the prescribing process and integrating into daily practice workflows. HarrowRx aims to streamline prescription fulfillment, patient support, and affordability programs, making it easier for patients to receive their prescribed ophthalmic medicines.

Trading the Move, Not the Narrative: (HROW) Edition

https://news.stocktradersdaily.com/news_release/89/Trading_the_Move,_Not_the_Narrative:_HROW_Edition_110126065401_1793577242.html
This article provides an AI-generated analysis of Harrow Health Inc. (NASDAQ: HROW), highlighting a potential shift in near-term sentiment and a strong risk-reward setup. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis, emphasizing current support and resistance levels.
Advertisement

BlackRock updates its passive stake above 5% in Harrow (HROW).

https://www.stocktitan.net/sec-filings/HROW/schedule-13g-a-harrow-inc-amended-passive-investment-disclosure-35ae5e88f00d.html
BlackRock, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Harrow, Inc. (HROW), reporting a beneficial ownership of 2,757,783 shares, which constitutes 7.4% of the common stock as of September 30, 2026. This filing indicates that BlackRock holds sole voting power over 2,692,848 shares and sole dispositive power over all 2,757,783 shares, with no shared powers. The report specifies that while various persons may receive dividends or sale proceeds, no single person's interest exceeded 5% of Harrow's outstanding common shares.

Harrow, Inc. (HROW) Latest Stock News & Headlines

https://ca.finance.yahoo.com/quote/HROW/news/
This article provides a compilation of recent news and headlines concerning Harrow, Inc. (HROW), an ophthalmic-focused pharmaceutical company. It includes announcements about upcoming financial results, recent acquisitions, participation in investor conferences, and analysis regarding its stock valuation and product pipeline. The article also presents HROW's trailing total returns compared to the S&P 500 benchmark.

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

https://www.manilatimes.net/2026/10/26/tmt-newswire/globenewswire/harrow-to-report-third-quarter-2026-financial-results-after-market-close-on-november-9-2026/2453846
Harrow (Nasdaq: HROW) announced it will report its financial results for the third quarter ended September 30, 2026, after market close on Monday, November 9, 2026. The company will also host a conference call and live webcast on Tuesday, November 10, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. A Letter to Stockholders will be posted to the "Investors" section of their website.

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

https://sg.finance.yahoo.com/news/harrow-report-third-quarter-2026-110000435.html
Harrow (Nasdaq: HROW) announced it will report its third-quarter 2026 financial results on Monday, November 9, 2026, after the market close. The company will also host a conference call and live webcast on Tuesday, November 10, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. A Letter to Stockholders will be posted on the company's website.

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

https://www.globenewswire.com/news-release/2026/10/26/3387968/0/en/harrow-to-report-third-quarter-2026-financial-results-after-market-close-on-november-9-2026.html
Harrow (Nasdaq: HROW) announced it will report its third-quarter 2026 financial results on Monday, November 9, 2026, after market close. The company will also host a conference call and live webcast on Tuesday, November 10, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. A Letter to Stockholders will be posted on the company's website in conjunction with the earnings release.
Advertisement

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

https://www.globenewswire.com/fr/news-release/2026/10/26/3387968/0/en/harrow-to-report-third-quarter-2026-financial-results-after-market-close-on-november-9-2026.html
Harrow (Nasdaq: HROW) announced it will report its financial results for the third quarter ended September 30, 2026, on Monday, November 9, 2026, after the market close. The company will also host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 10, 2026, to discuss the results and provide a business update. A Letter to Stockholders will be posted to the "Investors" section of its website.

Harrow, Inc. Estimates – NASDAQ:HROW

https://www.tradingview.com/symbols/NASDAQ-HROW/financials-estimates/
This page provides an overview of Harrow, Inc. (HROW) financial estimates on TradingView. It allows users to explore reported financial data and analyst estimates for the income statement, balance sheet, cash flow statement, and valuation metrics, comparing actual results with various estimates and visualizing trends.

Harrow, Inc. (3IP.F) recent insider transactions

https://au.finance.yahoo.com/quote/3IP.F/insider-transactions/
This article details recent insider transactions for Harrow, Inc. (3IP.F), including sales by Officer SHOJAEI AMIR and Beneficial Owner OPALEYE MANAGEMENT, INC., as well as purchases by Directors SILVERNAIL LAUREN P and GRAVES ADRIENNE L, and CEO BAUM MARK L. The data covers a two-year period, indicating various types of transactions such as sales, purchases, and conversions of derivative securities. The company's stock was trading at 24.00 EUR, down 3.23% as of the reporting time.

Harrow, Inc. (HROW) Stock Price and Chart — NASDAQ:HROW

https://www.tradingview.com/symbols/NASDAQ-HROW/
This page provides a detailed overview of Harrow, Inc. (HROW) stock, including its current price, key financial stats, upcoming earnings, and company information. It also features a collection of trading ideas and analyses from various users, along with technical indicators, analyst ratings, seasonal trends, and ETFs holding the stock. The article concludes with a comprehensive FAQ section addressing common questions about HROW's stock performance, forecasts, and financial details.

Harrow Inc. R (3IP.F) Q1 FY2026 earnings call transcript

https://finance.yahoo.com/quote/3IP.F/earnings/3IP.F-Q1-2026-earnings_call-579682.html
Harrow Inc. reported Q1 FY2026 revenue of $44.2M and an Adjusted EBITDA of -$12.7M, affected by an $8M VEVYE gross-to-net adjustment. Despite this, demand for key products like VEVYE, IHEEZO, and TRIESENCE remains strong, with VEVYE surpassing Xiidra in prescriptions. The company reaffirmed its full-year revenue guidance of $350M-$365M, anticipating accelerated growth from Q2 onwards.
Advertisement

Harrow, Inc. (3IP.F) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/3IP.F/latest-news/
This page provides a summary of Harrow, Inc. (3IP.F) stock information, including its current price of 24.00 EUR from a delayed quote on October 23. It lists recent news articles related to Harrow (HROW), discussing topics like fair value based on sales, options trading, ophthalmic pipeline buzz, product momentum, and Q2 earnings. The page also presents a performance overview comparing 3IP.F to the S&P 500, though specific return data for 3IP.F is unavailable.

Harrow secures TYRVAYA rights and adds a 2027 test for Harrow Health stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/harrow-secures-tyrvaya-rights-and-adds-a-2027-test-for-harrow-health-stock/70334175
Harrow Health (HROW) has acquired worldwide rights to TYRVAYA (excluding Japan) for an upfront payment of USD 30 million and potential milestone payments of up to USD 70 million. This acquisition, completed on October 5, 2026, is expected to add over USD 30 million in revenue during 2027 and expand Harrow's dry-eye treatment portfolio alongside VEVYE. The company's stock was last quoted at USD 28.75 on October 15, 2026, with a market capitalization of USD 1.1 billion.

(HROW) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/139/HROW_and_the_Role_of_Price-Sensitive_Allocations_101226093201_1791811921.html
This article provides an analysis of Harrow Health Inc. (NASDAQ: HROW), highlighting weak sentiment across all time horizons supporting a short bias. It details AI-generated institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for HROW.

Harrow, Inc. (HROW) stock price, news, quote and history

https://au.finance.yahoo.com/quote/HROW/
This article provides detailed financial information for Harrow, Inc. (HROW), an eyecare pharmaceutical company. It includes stock performance data, key financial metrics, company overview, earnings trends, and analyst ratings, showing a recent stock price of $28.42 and an average analyst target of $65.00. The company specializes in ophthalmic pharmaceutical products and has seen significant long-term growth despite recent dips.

Harrow, Inc. (HROW) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/HROW/
This article provides a detailed financial overview of Harrow, Inc. (HROW), an eyecare pharmaceutical company. It includes current stock performance, key financial metrics, an overview of its products and operations, and analyst ratings, with a target price of $65.00. The company recently changed its name from Harrow Health, Inc. in September 2023.
Advertisement

Harrow stock hits 52-week low at 28.51 USD

https://www.investing.com/news/company-news/harrow-stock-hits-52week-low-at-2851-usd-93CH-4941307
Harrow (HROW) stock has fallen to a new 52-week low of $28.51, currently trading just above this floor. Despite an InvestingPro analysis suggesting the stock is oversold and undervalued, the company recently reported a wider-than-expected loss in Q2 2026, though revenue increased.

Harrow stock hits 52-week low at 28.51 USD

https://ng.investing.com/news/stock-market-news/harrow-stock-hits-52week-low-at-2851-usd-93CH-2729462
Harrow (HROW) stock has dropped to a 52-week low of $28.51, currently trading at $28.62, representing a 38% year-to-date decline. Despite the downturn, InvestingPro suggests the stock is oversold and potentially undervalued, with analysts maintaining a "Strong Buy" consensus. The company recently reported a wider-than-expected loss for Q2 2026, though revenue increased and management reaffirmed its full-year outlook.

Do Options Traders Know Something About Harrow Stock We Don't?

https://www.tradingview.com/news/zacks:569681b1e094b:0-do-options-traders-know-something-about-harrow-stock-we-don-t/
Options traders are showing significant interest in Harrow, Inc. (HROW) as indicated by the high implied volatility in its Oct. 16, 2026 $15.00 Call options. This suggests expectations of a substantial price movement, although analysts currently rate Harrow as a Zacks Rank #3 (Hold). The implied volatility could also signal an opportunity for experienced options traders to sell premium, betting that the stock's movement will be less than expected.

Harrow, Inc. (HROW) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/HROW/
This article provides a comprehensive overview of Harrow, Inc. (HROW), an eyecare pharmaceutical company. It includes detailed stock information such as price movements, key statistics, financial highlights, and analyst ratings. The company's profile, including its products like IHEEZO, VEVYE, and various biosimilars, and its segments Branded and ImprimisRx, are also outlined.

Harrow Price Target Maintained With a $63.00/Share by BTIG

https://www.moomoo.com/news/post/1000685807/harrow-price-target-maintained-with-a-63-00-share-by
BTIG has reaffirmed its Buy rating for Harrow (NASDAQ: HROW) and maintained a price target of $63.00 per share. This analyst action indicates continued confidence in the company's stock performance.
Advertisement

HROW Reiterated by BTIG -- Price Target Maintained at $63

https://www.gurufocus.com/news/9112937/hrow-reiterated-by-btig-price-target-maintained-at-63
BTIG analyst Thomas Shrader has reiterated a Buy rating for Harrow Inc (HROW), maintaining a price target of $63.00, reflecting confidence in the ophthalmic products company. Harrow Inc is deemed undervalued by 32.4% with a GF Value™ of $44.91 against a current price of $30.35, despite being unprofitable. The company has a strong GF Score™ of 81/100, though its financial strength is weaker, and there has been recent insider selling activity.

Analysts’ Top Healthcare Picks: GE Healthcare Technologies Inc (GEHC), Harrow Health (HROW)

https://www.theglobeandmail.com/investing/markets/stocks/HROW/pressreleases/4986280/analysts-top-healthcare-picks-ge-healthcare-technologies-inc-gehc-harrow-health-hrow/
Two analysts have issued bullish sentiments on GE Healthcare Technologies Inc (GEHC) and Harrow Health (HROW). Needham analyst David Saxon reiterated a Buy rating on GE Healthcare with a $93.00 price target, while William Blair's Lachlan Hanbury Brown maintained a Buy rating on Harrow Health. GE Healthcare has a Moderate Buy consensus with a 25.3% upside, and Harrow Health has a Strong Buy consensus with a 104.7% upside.

Harrow Closes Acquisition of TYRVAYA®

https://www.globenewswire.com/news-release/2026/10/05/3374393/0/en/harrow-closes-acquisition-of-tyrvaya.html
Harrow Inc. has completed its acquisition of TYRVAYA® (varenicline solution) nasal spray from Viatris Inc., gaining worldwide rights except for Japan. This acquisition adds a unique, FDA-approved nasal spray for dry eye disease to Harrow's ocular surface franchise, complementing their existing product VEVYE®. The deal, valued at up to $100 million including milestone payments, is expected to significantly expand Harrow's market position and commercial capabilities in the dry eye treatment sector.

Harrow invests $30 million in new pharmaceutical as it builds portfolio

https://www.bizjournals.com/nashville/news/2026/10/05/harrow-invests-millions-dry-eye-drug-tyrvaya.html
Harrow has invested $30 million in a new nasal spray for dry eye disease, with a potential to spend an additional $70 million on the deal. This acquisition is expected to significantly impact the company's revenue as it expands its pharmaceutical portfolio.

Harrow completes $30M acquisition of TYRVAYA nasal spray

https://www.investing.com/news/company-news/harrow-completes-30m-acquisition-of-tyrvaya-nasal-spray-93CH-4931781
Harrow Inc. has completed its acquisition of TYRVAYA nasal spray from Viatris Inc. for an upfront payment of $30 million, with potential additional milestone payments up to $70 million. This deal grants Harrow worldwide rights to TYRVAYA, excluding Japan, and expands its commercial team for dry eye treatments. Harrow expects TYRVAYA to generate over $30 million in revenue in 2027.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement